Cyclacel Pharma (CYCC) Tops Q3 EPS by 4c

Cyclacel Pharma (NASDAQ: CYCC) reported Q3 EPS of ($0.22), $0.04 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $309 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• S&P 500 above 8,000 in 2026 now looks ambitious, Citi says
• Premarket movers: Oracle surges on AI growth, ACV auctions jumps on $1.9B deal